BridgeBio Pharma Inc(BBIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.57 | Insider Own | 10.45% | Shs Outstand | 195.3M | Perf Week | 0.31% |
| Market Cap | 13.32B | Forward P/E | - | EPS next Y | 83.42% | Insider Trans | -2.71% | Shs Float | 175.1M | Perf Month | 3.93% |
| Enterprise Value | 16.01B | PEG | - | EPS next Q | -0.54 | Inst Own | 91.28% | Short Float | 11.24% | Perf Quarter | -20.34% |
| Income | -0.69B | P/S | 18.68 | EPS this Y | 26.96% | Inst Trans | -3.06% | Short Ratio | 7.98 | Perf Half Y | -8.55% |
| Sales | 0.71B | P/B | - | EPS next 5Y | - | ROA | -60.23% | Short Interest | 19.67M | Perf YTD | -10.9% |
| Book/sh | -12.88 | P/C | 18.49 | EPS past 3/5Y | -5.07% 0.09% | ROE | - | 52W High | -27.05% ($93.42) | Perf Year | 25.6% |
| Cash/sh | 3.69 | P/FCF | - | Sales past 3/5Y | 86.3% 127.44% | ROIC | -225.61% | 52W Low | 25.67% ($54.23) | Perf 3Y | 171.84% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 12.83% | Gross Margin | 94.12% | Volatility(W/M) | 2.39% 3.07% | Perf 5Y | 38.85% |
| Dividend TTM | - | EV/Sales | 22.46 | Sales Y/Y TTM | 202.39% | Oper. Margin | -67.01% | ATR (14) | 2.12 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.17 | EPS Q/Q | 18.57% | Profit Margin | -97.03% | RSI (14) | 50.5 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.23 | Sales Q/Q | 120.39% | SMA20 | 2.37% ($66.57) | Beta | 0.99 | Target Price | $110.47 |
| Payout | - | Debt/Eq | - | Earnings | 2026/10/29 | SMA50 | -4.22% ($71.15) | Rel Volume | 0.84 | Prev Close | $68.56 |
| Employees | 839 | LT Debt/Eq | - | EPS/Sales Surpr. | -35.51% 10.31% | SMA200 | -6.48% ($72.87) | Avg Volume(3M) | 2.46M | Price | $68.15 |
| IPO | 2019/6/27 | Option/Short | Yes/Yes | Trades | 19846 | Volume | 2,059,180 | Change | -0.6% |
A U.S. biotech company specializing in genetic disorders, developing and commercializing therapies targeting rare diseases with identified genetic causes and related cancers, with a core focus on treatments for cardiac conditions as a rare disease-focused biotech company.
Over the past 1 year, roughly in the middle
27% below its 1-year high.
Traded about as much as usual. That is 84% of its average volume.
Next earnings report: October 29
2 days to go.
BBIO has weak earning power
Of every $100 in sales, $67.01 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +27.0% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,868. Peers typically go for $906.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +38.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 91.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #18 of 594 in the industry
Based on market cap of $13B.
HALO#16 Halozyme Therapeutics Inc $15B PER 38.3 
JAZZ#17 Jazz Pharmaceuticals plc $13B PER 14.2 BBIO#18 BridgeBio Pharma Inc $13B PER - 
SMMT#19 Summit Therapeutics Inc $12B PER - 
TECH#20 Bio-Techne Corp $11B PER 62.8 
FAQ
What kind of company is BBIO?
BBIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BBIO?
The market cap of BBIO is approximately $13.3B, ranking 760 within its sector.
What is the 52-week high and low for BBIO?
BBIO has recorded a 52-week high of $93.42 and a low of $54.23.
